CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The ME.15 (MelMarT-II) phase III randomized control trial investigating 1cm vs 2cm wide excision margins for primary cutaneous melanoma has closed to accrual after reaching the accrual target of 3000 patients enrolled. This study is investigating the use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient and improve quality of lift.
The CCTG HD11 study, a Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma has closed to accrual. This purpose of this study was to determine if treatment with Pembrolizumab and Brentuximab vedotin is better or worse than the standard of care for classical Hodgkin lymphoma.
For more information > CCTG HD11 members trial page.
CCTG is upgrading our login platform to Auth0 by Okta for a more secure and seamless login experience. The new login screen is designed to be simple and user-friendly, allowing you to log in using your existing credentials. This change ensures faster, more reliable access to your account with fewer sign ins, while keeping your data safe.
